Home › Mantle Cell Lymphoma › New Jersey
Mantle Cell Lymphoma clinical trials in New Jersey
8 studies for Mantle Cell Lymphoma are looking for participants at sites in New Jersey.
Cities in New Jersey
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Hackensack
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- The Valley Hospital, Inc, Paramus
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06742996A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Hackensack
- Research Site, New Brunswick
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06564038A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START New Jersey, East Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833SynKIR-310 for Relapsed/Refractory B-NHL
- Rutgers Cancer Institute, New Brunswick
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265Study of SGR-1505 in Mature B-Cell Neoplasms
- Regional Cancer Care Associates, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Brunswick
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.